2024
Effectiveness of Original Monovalent and Bivalent COVID‐19 Vaccines Against COVID‐19‐Associated Hospitalization and Severe In‐Hospital Outcomes Among Adults in the United States, September 2022–August 2023
DeCuir J, Surie D, Zhu Y, Lauring A, Gaglani M, McNeal T, Ghamande S, Peltan I, Brown S, Ginde A, Steinwand A, Mohr N, Gibbs K, Hager D, Ali H, Frosch A, Gong M, Mohamed A, Johnson N, Srinivasan V, Steingrub J, Khan A, Busse L, Duggal A, Wilson J, Qadir N, Chang S, Mallow C, Kwon J, Exline M, Shapiro N, Columbus C, Vaughn I, Ramesh M, Safdar B, Mosier J, Casey J, Talbot H, Rice T, Halasa N, Chappell J, Grijalva C, Baughman A, Womack K, Rhoads J, Swan S, Johnson C, Lewis N, Ellington S, Dawood F, McMorrow M, Self W, Network F. Effectiveness of Original Monovalent and Bivalent COVID‐19 Vaccines Against COVID‐19‐Associated Hospitalization and Severe In‐Hospital Outcomes Among Adults in the United States, September 2022–August 2023. Influenza And Other Respiratory Viruses 2024, 18: e70027. PMID: 39496339, PMCID: PMC11534416, DOI: 10.1111/irv.70027.Peer-Reviewed Original ResearchConceptsCOVID-19-associated hospitalizationIn-hospital outcomesVaccine effectivenessMonovalent dosesAbsolute VETest-negative case-control designInvasive mechanical ventilationCOVID-19 vaccineMultivariate logistic regressionSevere COVID-19Case patientsCase-control designControl patientsMechanical ventilationUnvaccinated patientsPatientsMonovalent vaccineCOVID-19-like illnessDoseCOVID-19 vaccine effectivenessBivalent vaccineLogistic regressionAdmission dateVaccineHospitalEffectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity—IVY Network, 26 Hospitals, 18 October 2023–9 March 2024
C K, Surie D, Lauring A, Martin E, Leis A, Papalambros L, Gaglani M, Columbus C, Gottlieb R, Ghamande S, Peltan I, Brown S, Ginde A, Mohr N, Gibbs K, Hager D, Saeed S, Prekker M, Gong M, Mohamed A, Johnson N, Srinivasan V, Steingrub J, Khan A, Hough C, Duggal A, Wilson J, Qadir N, Chang S, Mallow C, Kwon J, Parikh B, Exline M, Vaughn I, Ramesh M, Safdar B, Mosier J, Harris E, Shapiro N, Felzer J, Zhu Y, Grijalva C, Halasa N, Chappell J, Womack K, Rhoads J, Baughman A, Swan S, Johnson C, Rice T, Casey J, Blair P, Han J, Ellington S, Lewis N, Thornburg N, Paden C, Atherton L, Self W, Dawood F, DeCuir J. Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity—IVY Network, 26 Hospitals, 18 October 2023–9 March 2024. Clinical Infectious Diseases 2024, ciae405. PMID: 39107255, DOI: 10.1093/cid/ciae405.Peer-Reviewed Original ResearchInvasive mechanical ventilationIntensive care unitCase-patientsOdds of severe outcomesCOVID-19 vaccineLogistic regressionOdds of ICU admissionCOVID-19 vaccine dosesControl-patientsAnalyzed patientsImmune escapeCase-control designVaccine compositionMechanical ventilationClinical severityICU admissionVaccine doseCare unitTest-negativeVaccine effectivenessSevere outcomesCOVID-19-like illnessCOVID-19 vaccine effectivenessSARS-CoV-2HospitalSeverity of Respiratory Syncytial Virus vs COVID-19 and Influenza Among Hospitalized US Adults
Surie D, Yuengling K, DeCuir J, Zhu Y, Lauring A, Gaglani M, Ghamande S, Peltan I, Brown S, Ginde A, Martinez A, Mohr N, Gibbs K, Hager D, Ali H, Prekker M, Gong M, Mohamed A, Johnson N, Srinivasan V, Steingrub J, Leis A, Khan A, Hough C, Bender W, Duggal A, Bendall E, Wilson J, Qadir N, Chang S, Mallow C, Kwon J, Exline M, Shapiro N, Columbus C, Vaughn I, Ramesh M, Mosier J, Safdar B, Casey J, Talbot H, Rice T, Halasa N, Chappell J, Grijalva C, Baughman A, Womack K, Swan S, Johnson C, Lwin C, Lewis N, Ellington S, McMorrow M, Martin E, Self W. Severity of Respiratory Syncytial Virus vs COVID-19 and Influenza Among Hospitalized US Adults. JAMA Network Open 2024, 7: e244954. PMID: 38573635, PMCID: PMC11192181, DOI: 10.1001/jamanetworkopen.2024.4954.Peer-Reviewed Original ResearchConceptsInvasive mechanical ventilationRespiratory syncytial virusSeverity of RSV diseaseInfluenza diseaseVaccinated patientsIn-hospital deathUnvaccinated patientsRSV diseaseSyncytial virusClinical decision-makingComposite of invasive mechanical ventilationOutcome of invasive mechanical ventilationSeverity of respiratory syncytial virusLaboratory-confirmed respiratory syncytial virusHospitalized US adultsInfluenza vaccination statusVaccination statusAcute respiratory illnessMultivariate logistic regressionCenters for Disease Control and PreventionSeverity of COVID-19Disease Control and PreventionInfluenza infectionInfluenza severityClinical outcomes
2023
Vaccine Effectiveness Against Influenza A–Associated Hospitalization, Organ Failure, and Death: United States, 2022–2023
Lewis N, Zhu Y, Peltan I, Gaglani M, McNeal T, Ghamande S, Steingrub J, Shapiro N, Duggal A, Bender W, Taghizadeh L, Brown S, Hager D, Gong M, Mohamed A, Exline M, Khan A, Wilson J, Qadir N, Chang S, Ginde A, Mohr N, Mallow C, Lauring A, Johnson N, Gibbs K, Kwon J, Columbus C, Gottlieb R, Raver C, Vaughn I, Ramesh M, Johnson C, Lamerato L, Safdar B, Casey J, Rice T, Halasa N, Chappell J, Grijalva C, Talbot H, Baughman A, Womack K, Swan S, Harker E, Price A, DeCuir J, Surie D, Ellington S, Self W, Calhoun N, Murthy K, Cravens J, Herrick J, McKillop A, Hoffman E, Graves A, Zayed M, Smith M, Scott B, Health W, Fisher T, Hurutado-Rodriguez M, Kruse T, Dunkley S, Perez G, Bychkowski A, Grefsrud T, Calhoun N, Murthy K, Herrick J, Smith M, Steingrub J, Kozikowski L, De Souza L, Ouellette S, Shapiro N, Bolstad M, Coviello B, Ciottone R, Devilla A, Grafals A, Higgins C, Ottanelli C, Redman K, Scaffidi D, Weingart A, Surie D, McMorrow M, DeCuir J, Lewis N, Harker E, Ellington S, Mehkri O, Mitchell M, Griffith Z, Brennan C, Ashok K, Poynter B, Duggal A, Busse L, Lohuis C, Stanley N, Zhang S, Prekker M, Frosch A, Hendrickson A, Douglas S, Hurreh K, Peltan I, Smith C, Marshall H, Hager D, Ali H, Phan M, Gong M, Mohamed A, Nair R, Chen J, Exline M, Karow S, Khan M, So M, Snyder C, Swoope G, Smith D, Lee B, Rasul A, Pathak M, Lewald Z, Wilson R, Khan A, Peña J, Briceno G, Ahmed C, Martinez J, Pocius E, Oh M, Hyde J, Gause S, Wilson J, Gordon A, Perez C, Lau L, Bekiroglu I, Tran C, Frankel T, Garner O, Chandrasekaran S, Ginde A, Douin D, Martinez A, Huynh D, Steinwand A, Sullivan A, Withers C, Mohr N, Zepeski A, Nassar P, Landers S, Nielsen K, Briggs N, Fairfield C, Peebles A, Mallow C, Rivas C, Martin E, Monto A, Lauring A, McSpadden E, Truscon R, Kaniclides A, Thomas L, Bielak R, Valvano W, Fong R, Fitzsimmons W, Blair C, Gilbert J, Papalambros L, Holz A, Johnson N, Srinivasan V, Crider C, Steinbock K, Paulsen T, Anderson L, Self W, Talbot H, Grijalva C, Jones I, Halasa N, Chappell J, Womack K, Rhoads J, Baughman A, Kampe C, Johnson J, Swan S, Johnson C, Zhu Y, Rice T, Casey J, Stubblefield W, Zhu Y, Short L, Ezzell L, Whitsett M, McHenry R, Hargrave S, Blair M, Luther J, Pulido C, Peterson B, Files D, Gibbs K, Landreth L, Hicks M, Parks L, Kwon J, Parikh B, McDonald D, Samuels C, Vogt L, O’Neil C, Valencia A, Hink T, Bychkowski A, Dunkley S, Fisher T, Grefsrud T, Hurutado-Rodriguez M, Perez G, Beney K, Jayaprakash R, Koneru S, Lava J, Pinderi Z, Resk M, Goyal A, DeLamielleure L, Kosover M, Brokowski C. Vaccine Effectiveness Against Influenza A–Associated Hospitalization, Organ Failure, and Death: United States, 2022–2023. Clinical Infectious Diseases 2023, 78: 1056-1064. PMID: 38051664, PMCID: PMC11487098, DOI: 10.1093/cid/ciad677.Peer-Reviewed Original ResearchInfluenza-associated hospitalizationsVaccine effectivenessOrgan failureInfluenza vaccineSevere acute respiratory syndrome coronavirus 2Current season influenza vaccinationAcute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2Influenza-associated outcomesInvasive mechanical ventilationAcute respiratory illnessSentinel Surveillance NetworkTest-negative designSyndrome coronavirus 2Close antigenic matchInfluenza vaccinationRespiratory failureRenal failureInfluenza seasonMechanical ventilationOrgan supportSupplemental oxygenRespiratory illnessCoronavirus 2Influenza circulation1108. Severity of Illness among Adults Hospitalized with Respiratory Syncytial Virus Compared with COVID-19 and Influenza — IVY Network, 25 Hospitals, 20 U.S. States, January 31, 2022 – April 11, 2023
Yuengling K, Surie D, DeCuir J, Zhu Y, Gaglani M, Ginde A, Gibbs K, Prekker M, Mohamed A, Johnson N, Peltan I, Bender W, Mallow C, Kwon J, Lauring A, Columbus C, Vaughn I, Safdar B, Chappell J, Baughman A, Swan S, Johnson C, McMorrow M, Self W, Martin E. 1108. Severity of Illness among Adults Hospitalized with Respiratory Syncytial Virus Compared with COVID-19 and Influenza — IVY Network, 25 Hospitals, 20 U.S. States, January 31, 2022 – April 11, 2023. Open Forum Infectious Diseases 2023, 10: ofad500.081. PMCID: PMC10678102, DOI: 10.1093/ofid/ofad500.081.Peer-Reviewed Original ResearchInvasive mechanical ventilationAcute respiratory illnessAdvanced respiratory supportSARS-CoV-2Respiratory supportRespiratory illnessCOVID-19Use of IMVHigh-flow nasal cannulaMultivariable logistic regression modelAsahi Kasei PharmaMedical condition categoriesSeverity of RSVFlow nasal cannulaInfluenza-associated hospitalizationsNon-invasive ventilationShortness of breathSeverity of illnessRespiratory syncytial virusSevere respiratory illnessGrant/research supportChi-square testLogistic regression modelsPrevalence of RSVMedian ageDisease Severity of Respiratory Syncytial Virus Compared with COVID-19 and Influenza Among Hospitalized Adults Aged ≥60 Years — IVY Network, 20 U.S. States, February 2022–May 2023
Surie D, Yuengling K, DeCuir J, Zhu Y, Gaglani M, Ginde A, Talbot H, Casey J, Mohr N, Ghamande S, Gibbs K, Files D, Hager D, Ali H, Prekker M, Gong M, Mohamed A, Johnson N, Steingrub J, Peltan I, Brown S, Leis A, Khan A, Hough C, Bender W, Duggal A, Wilson J, Qadir N, Chang S, Mallow C, Kwon J, Exline M, Lauring A, Shapiro N, Columbus C, Vaughn I, Ramesh M, Safdar B, Halasa N, Chappell J, Grijalva C, Baughman A, Rice T, Womack K, Han J, Swan S, Mukherjee I, Lewis N, Ellington S, McMorrow M, Martin E, Self W, Network I. Disease Severity of Respiratory Syncytial Virus Compared with COVID-19 and Influenza Among Hospitalized Adults Aged ≥60 Years — IVY Network, 20 U.S. States, February 2022–May 2023. MMWR Morbidity And Mortality Weekly Report 2023, 72: 1083-1088. PMID: 37796753, PMCID: PMC10564326, DOI: 10.15585/mmwr.mm7240a2.Peer-Reviewed Original ResearchConceptsHigh-flow nasal cannulaInvasive mechanical ventilationRSV disease severityNoninvasive ventilationDisease severityCOVID-19Intensive care unit admissionRespiratory syncytial virus vaccinationOlder adultsLaboratory-confirmed RSVCare unit admissionAcute respiratory illnessFlow oxygen therapyMultivariable logistic regressionCDC's Advisory CommitteeRespiratory syncytial virusSARS-CoV-2Advisory CommitteeUnit admissionICU admissionImmunization PracticesRSV vaccinationVirus vaccinationAdults AgedInfluenza severity